JP2010506921A - 炎症性疾患における４−１ｂｂリガンド - Google Patents

炎症性疾患における４−１ｂｂリガンド Download PDF

Info

Publication number
JP2010506921A
JP2010506921A JP2009533352A JP2009533352A JP2010506921A JP 2010506921 A JP2010506921 A JP 2010506921A JP 2009533352 A JP2009533352 A JP 2009533352A JP 2009533352 A JP2009533352 A JP 2009533352A JP 2010506921 A JP2010506921 A JP 2010506921A
Authority
JP
Japan
Prior art keywords
1bbl
amino acid
polypeptide
seq
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009533352A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010506921A5 (cg-RX-API-DMAC10.html
Inventor
カン，ヨン・ジュン
ハン，ジアファイ
Original Assignee
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2010506921A publication Critical patent/JP2010506921A/ja
Publication of JP2010506921A5 publication Critical patent/JP2010506921A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
JP2009533352A 2006-10-16 2007-10-16 炎症性疾患における４−１ｂｂリガンド Withdrawn JP2010506921A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85202206P 2006-10-16 2006-10-16
US91756107P 2007-05-11 2007-05-11
PCT/US2007/022103 WO2008057171A2 (en) 2006-10-16 2007-10-16 4-1 bb ligand in inflammatory diseases

Publications (2)

Publication Number Publication Date
JP2010506921A true JP2010506921A (ja) 2010-03-04
JP2010506921A5 JP2010506921A5 (cg-RX-API-DMAC10.html) 2010-09-30

Family

ID=39364965

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009533352A Withdrawn JP2010506921A (ja) 2006-10-16 2007-10-16 炎症性疾患における４−１ｂｂリガンド

Country Status (11)

Country Link
US (1) US20100098689A1 (cg-RX-API-DMAC10.html)
EP (1) EP2097454A2 (cg-RX-API-DMAC10.html)
JP (1) JP2010506921A (cg-RX-API-DMAC10.html)
KR (1) KR20090068376A (cg-RX-API-DMAC10.html)
AU (1) AU2007318219A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0717744A2 (cg-RX-API-DMAC10.html)
CA (1) CA2666306A1 (cg-RX-API-DMAC10.html)
IL (1) IL197637A0 (cg-RX-API-DMAC10.html)
MX (1) MX2009004021A (cg-RX-API-DMAC10.html)
RU (1) RU2009110153A (cg-RX-API-DMAC10.html)
WO (1) WO2008057171A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100183633A1 (en) * 2008-12-04 2010-07-22 University Of Massachusetts Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040248157A1 (en) * 2001-09-14 2004-12-09 Michal Ayalon-Soffer Novel polynucleotides encoding soluble polypeptides and methods using same

Also Published As

Publication number Publication date
IL197637A0 (en) 2011-08-01
WO2008057171A2 (en) 2008-05-15
WO2008057171A3 (en) 2008-11-20
KR20090068376A (ko) 2009-06-26
US20100098689A1 (en) 2010-04-22
RU2009110153A (ru) 2010-11-27
AU2007318219A1 (en) 2008-05-15
BRPI0717744A2 (pt) 2013-11-12
EP2097454A2 (en) 2009-09-09
MX2009004021A (es) 2009-08-12
CA2666306A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
JP5859307B2 (ja) 眼の血管新生を阻害する方法
US8187596B1 (en) Method of treating asthma or allergy by administering an IL-33 receptor antibody
Kang et al. Cell surface 4-1BBL mediates sequential signaling pathways' downstream'of TLR and is required for sustained TNF production in macrophages
US20110311555A1 (en) Tc11 as a Transcriptional Regulator
US20100183633A1 (en) Interleukin 6 and tumor necrosis factor alpha as biomarkers of jnk inhibition
JP6689484B2 (ja) 網膜炎症の治療において使用するための薬剤
JP5051454B2 (ja) アポトーシス促進剤、細胞増殖阻害剤、癌の予防・治療剤、及びそのスクリーニング方法
JP2005532256A (ja) 慢性関節リウマチを治療するためのｌｉｒ機能の調節
US20220370463A1 (en) Stabilized c-fms intracellular fragments (ficd) promote osteoclast differentiation and arthritic bone erosion
CN101528779A (zh) 炎症性疾病中的4-1bb配体
TW200831898A (en) Treatment of insulin resistance
WO2001088191A1 (en) A novel specific inhibitor of the cyclin kinase inhibitor p21?waf1/cip1¿
US20100098689A1 (en) 4-1 bb ligand in inflammatory diseases
WO2009084668A1 (ja) 癌細胞増殖阻害方法、増殖阻害剤及びスクリーニング方法
JPWO2008111520A1 (ja) 寿命延長関連遺伝子およびその用途
JP2006129724A (ja) ラクリチン活性を有する化合物のスクリーニング方法
JP2016104716A (ja) 膵臓癌治療用のｃｄ９５シグナル伝達阻害化合物
US20070004657A1 (en) Diagnosis and treatment of kidney fibrosis and other fibrotic diseases
EP1557178A1 (en) Use of sglt homolog
HK1134304A (en) 4-1 bb ligand in inflammatory diseases
US20110306655A1 (en) Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
EP1600165A1 (en) Medicinal use of mip-3alpha inhibitor and method of screening brain/nerve cell protective agent
CN106102766A (zh) 用于治疗视网膜炎症的试剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100812

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100812

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110201